SECOND AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2023 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO CONSULTING AGREEMENT (“Second Amendment”) is made and entered into on 26 September 2023, by and among RespireRx Pharmaceuticals Inc. (the ‘COMPANY’), a New Jersey corporation and DNA Healthlink, Inc., a New Jersey Corporation together with its President, Richard Purcell (the ‘CONSULTANT’), who will serve as Senior Vice President Research and Development for RespireRx, with responsibilities for such duties as are normally associated with the position.
SETTLEMENT AND EXCHANGE AGREEMENTSettlement and Exchange Agreement • October 2nd, 2023 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations
AGREEMENT made this 26th day of September 2023 by and between DNA Healthlink, Inc. (“DNA Healthlink”) and RespireRx Pharmaceuticals Inc. (RespireRx”). DNA Healthlink and RespireRx are referred to herein individually as “Party” and together as “Parties.”
